^
    Back
    Association details:
    Biomarker:AR positive
    Cancer:Salivary Gland Cancer
    Drug:Nubeqa (darolutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

    Excerpt:
    ...Histologically confirmed as androgen receptor-positive salivary gland carcinoma at the medical institution....
    Trial ID:
    DISCOVARY
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.

    Published date:
    05/25/2023
    Excerpt:
    This is the first prospective trial of darolutamide for AR-positive SGC. The response rate by ICR and other secondary endpoints confirmed clinically meaningful activity and a well-tolerated safety profile.
    DOI:
    10.1200/JCO.2023.41.16_suppl.6093
    Trial ID:
    DISCOVARY